1. Home
  2. AVDL vs IMNM Comparison

AVDL vs IMNM Comparison

Compare AVDL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • IMNM
  • Stock Information
  • Founded
  • AVDL 2015
  • IMNM 2006
  • Country
  • AVDL Ireland
  • IMNM United States
  • Employees
  • AVDL N/A
  • IMNM N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • IMNM Medicinal Chemicals and Botanical Products
  • Sector
  • AVDL Health Care
  • IMNM Health Care
  • Exchange
  • AVDL Nasdaq
  • IMNM Nasdaq
  • Market Cap
  • AVDL 784.6M
  • IMNM 770.1M
  • IPO Year
  • AVDL 1996
  • IMNM 2020
  • Fundamental
  • Price
  • AVDL $9.39
  • IMNM $7.46
  • Analyst Decision
  • AVDL Strong Buy
  • IMNM Strong Buy
  • Analyst Count
  • AVDL 7
  • IMNM 5
  • Target Price
  • AVDL $18.86
  • IMNM $26.40
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • IMNM 1.1M
  • Earning Date
  • AVDL 05-07-2025
  • IMNM 05-16-2025
  • Dividend Yield
  • AVDL N/A
  • IMNM N/A
  • EPS Growth
  • AVDL N/A
  • IMNM N/A
  • EPS
  • AVDL N/A
  • IMNM N/A
  • Revenue
  • AVDL $194,450,000.00
  • IMNM $9,041,000.00
  • Revenue This Year
  • AVDL $50.53
  • IMNM N/A
  • Revenue Next Year
  • AVDL $32.33
  • IMNM $1,259.12
  • P/E Ratio
  • AVDL N/A
  • IMNM N/A
  • Revenue Growth
  • AVDL 252.64
  • IMNM N/A
  • 52 Week Low
  • AVDL $6.38
  • IMNM $5.15
  • 52 Week High
  • AVDL $17.85
  • IMNM $19.07
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 64.66
  • IMNM 43.56
  • Support Level
  • AVDL $8.55
  • IMNM $7.15
  • Resistance Level
  • AVDL $9.98
  • IMNM $9.16
  • Average True Range (ATR)
  • AVDL 0.51
  • IMNM 0.51
  • MACD
  • AVDL 0.10
  • IMNM -0.08
  • Stochastic Oscillator
  • AVDL 72.04
  • IMNM 15.42

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: